Novartis and Sanofi, two of the world’s largest drugmakers, are focusing on subcutaneous (SC) versions of their top-selling products to achieve longer lasting effects and easier administration. According to a report from FirstWord Pharma, both companies believe SC formulations can extend the market life of their drugs and improve patient adherence. These efforts reflect a broader industry push toward more convenient injectable therapies.

Key Takeaways

  • Novartis and Sanofi are developing subcutaneous versions of key drugs to prolong their commercial longevity.
  • SC formulations offer easier self administration compared to intravenous infusions, potentially boosting patient compliance.
  • The shift aims to protect revenue from biosimilar competition and meet patient demand for simpler treatment options.
  • Both companies are betting that SC delivery will differentiate their products in crowded markets.

Why Subcutaneous Formulations Are Gaining Attention

Subcutaneous injections involve delivering medication into the fatty tissue just under the skin. This method is less invasive than intravenous (IV) infusions and can often be done by patients at home. For chronic conditions such as autoimmune diseases or cancer, SC formulations reduce the need for frequent clinic visits. The convenience may lead to better treatment adherence and improved outcomes. Drugmakers see SC versions as a way to extend the life of existing products before they face generic or biosimilar competition.

Novartis’s Strategy

Novartis is working on subcutaneous versions of several key products, including Cosentyx (secukinumab) for psoriasis and psoriatic arthritis, and possibly others in its immunology portfolio. The company has already tested SC formulations for multiple sclerosis drug Gilenya, though that product remains oral. By offering SC options, Novartis aims to provide patients with flexibility and potentially longer dosing intervals. The report notes that Novartis executives view SC delivery as a crucial component of their longevity plans for these drugs.

Sanofi’s Approach

Sanofi is focusing its SC efforts on Dupixent (dupilumab), a blockbuster treatment for asthma, atopic dermatitis, and other allergic conditions. The company is developing a higher concentration formulation that would allow less frequent injections. Sanofi also has other SC pipelines in immunology and rare diseases. The goal is to maintain Dupixent’s market dominance as biosimilars approach. According to the original report, Sanofi believes that convenient SC options will be essential for patient retention and expansion.

Broader Industry Implications

The moves by Novartis and Sanofi reflect a wider trend in the pharmaceutical industry. Many companies are reformulating IV drugs as SC injections to offer convenience and extend patent life. For example, Roche has SC versions of Herceptin and Rituxan. As biologics become more common, the ability to self inject at home is a major competitive advantage. The shift also aligns with patient preference for less time consuming treatments. However, developing stable SC formulations can be technically challenging and requires significant investment.

Potential Challenges and Considerations

Subcutaneous formulations are not always straightforward. Some biologics have large molecules that are difficult to absorb through subcutaneous tissue. High volumes may cause pain or swelling at the injection site. Companies must also prove that SC versions are as effective and safe as their IV counterparts through clinical trials. Regulatory approval and manufacturing scale up add further hurdles. Nonetheless, both Novartis and Sanofi appear committed to overcoming these obstacles to secure the longevity of their key products.

Frequently Asked Questions

What is a subcutaneous injection?

A subcutaneous injection delivers medication into the layer of fat between the skin and muscle. It is commonly used for drugs that need slow, steady absorption, such as insulin and some biologics. Patients can often self administer SC injections at home.

How do SC formulations extend drug longevity?

SC versions can offer longer dosing intervals or easier use, making them more attractive to patients and prescribers. This can delay the erosion of market share when cheaper biosimilars arrive. Companies can also file new patents on SC formulations, extending exclusive sales periods.

Are SC injections always better than IV infusions?

They are not always better, but they offer advantages like shorter administration time and reduced need for clinic visits. On the downside, larger injection volumes can be uncomfortable, and not all drugs can be formulated for SC delivery. The choice depends on the specific drug and patient needs.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.